Levetiracetam for the treatment of essential tremor [1]

Movement Disorders

Volumn 20, Issue 5, 2005, Pages 640-

  Sullivan, Kelly L ^a   Hauser, Robert A ^a   Zesiewicz, Theresa A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; LEVODOPA; PLACEBO;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EPWORTH SLEEPINESS SCALE; ESSENTIAL TREMOR; FEMALE; HUMAN; LETTER; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; METHODOLOGY; MOTOR DYSFUNCTION; MYOCLONUS; PARKINSON DISEASE; PATIENT ATTITUDE; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SOMNOLENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTICONVULSANTS; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX;

EID: 20844440358     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20437     Document Type: Letter

References (4)

1. Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004;19:1215-1221.
2. Physicians' Desk Reference. 58th ed. Montvale, NJ: Thompson PDR; 2004.
3. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112-1114.
4. Loscher W, Richter A. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur J Pharmacol 2000;391:251-254.